Investments
15Portfolio Exits
2Partners & Customers
2About Hadasit Bio Holdings
Hadasit Bio-Holdings Ltd. was founded and floated on the Tel Aviv Stock Exchange (TASE: HDST) in order to allow public participation in the promising field of biotechnology. It serves as a precedent in biotechnology financing - for the first time, public investment is allowed to participate in companies based on IP generated by Israel's foremost medical research center - the Hadassah University Hospital ("Hadassah"), which is responsible for much of Israel's hospital-based translational research.

Want to inform investors similar to Hadasit Bio Holdings about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Hadasit Bio Holdings News
Aug 3, 2022
03 August 2022 “Israel is a very, very entrepreneurial country. Many people are inventors, many people are not afraid to start new things. And people are not afraid to fail. We think that learning from your failure is very, very important.” - Tamar Raz, CEO at Hadasit Medical Research Services & Development You can also listen to this podcast episode on Apple and Google . SUBSCRIBE in order not to miss any new one: This episode of Techtalk features Tamar Raz, CEO at Hadasit Medical Research Services & Development, the technology transfer company of Hadassah University Hospitals in Jerusalem, and a Technology Transfer Expert with nearly 20 years of experience leading business transactions and management in the biotech and life sciences sector. Tamar is also the Director of KAHR-medical Ltd. and she serves as the chairperson of Hadasit Bio Holdings, a public holding company allowing public participation in the promising field of biotechnology. This conversation covers Tamar’s point of view about the technology transfer in Israel and her remarkable experience as an expert and entrepreneur who brings medical innovations from the laboratory to the market. Tamar starts with an historical overview of the technology transfer sector in Israel and continues by giving us precious insights about the technology transfer infrastructure, steps, phases and key departments. We discuss not only the basics of technology transfer, but also more advanced industry activities like the incubation or acceleration programmes, that can not exist without the infrastructure described before. IBM Alpha Zone - the first accelerator that IBM built in the world, located in Israel - is a great example. Moreover, Tamar shares lessons about how a technology transfer center like Hadasit can become financially sustainable and the importance of a flexible business model that means long-term investment and short-term activities that bring revenues. “We worked in Hadassah, in the last 4 or 5 years, to enlarge the innovation ecosystem of Hadassah. So, we want to bring companies to work with us not only based on our IP, but also based on their IP, on their ideas. Because we believe that connecting the physicians and professors of Hadasa to the industry and to the start-up companies, we create a cycle of innovation at Hadassah that will bring us more work and will bring us more revenues. But also we create better inventors that will think about the new ideas all the time”, Tamar explains. Tune in to find Tamar’s favorite Hadasit success story and: Historic overview of how Israel became such a great example of technology transfer (04:30) How the technology transfer infrastructure was built (10:30) The universities input in creating technology transfer departments (18:30) The first steps that Romania, or other countries with an undeveloped technology transfer sector, should take (26:00) Key departments for successful technology transfer (35:30) The differentiators of an incubation or acceleration programmes (39:00) Why Digital Health? (41:00) What makes a technology transfer center like Hadasit financially sustainable? (45:00) Tamar’s favorite Hadasit success story (48:30) The economic impact of the technology transfer in Israel (57:30)
Hadasit Bio Holdings Investments
15 Investments
Hadasit Bio Holdings has made 15 investments. Their latest investment was in KAHR as part of their Series D on June 6, 2021.

Hadasit Bio Holdings Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/16/2021 | Series D | KAHR | $46.5M | No | 15 | |
2/25/2020 | Series C | KAHR | $18M | No | 4 | |
9/19/2017 | Series B | Enlivex Therapeutics | $10M | No | 3 | |
9/10/2013 | Series A - III | |||||
1/22/2013 | Convertible Note |
Date | 6/16/2021 | 2/25/2020 | 9/19/2017 | 9/10/2013 | 1/22/2013 |
---|---|---|---|---|---|
Round | Series D | Series C | Series B | Series A - III | Convertible Note |
Company | KAHR | KAHR | Enlivex Therapeutics | ||
Amount | $46.5M | $18M | $10M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 15 | 4 | 3 |
Hadasit Bio Holdings Portfolio Exits
2 Portfolio Exits
Hadasit Bio Holdings has 2 portfolio exits. Their latest portfolio exit was Enlivex Therapeutics on March 26, 2019.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/26/2019 | Reverse Merger | 7 | |||
Date | 3/26/2019 | |
---|---|---|
Exit | Reverse Merger | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 7 |
Hadasit Bio Holdings Acquisitions
1 Acquisition
Hadasit Bio Holdings acquired 1 company. Their latest acquisition was Cell Cure Neurosciences on October 10, 2010.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
10/10/2010 | Corporate Majority |
Date | 10/10/2010 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Corporate Majority |
Sources |
Hadasit Bio Holdings Partners & Customers
2 Partners and customers
Hadasit Bio Holdings has 2 strategic partners and customers. Hadasit Bio Holdings recently partnered with Cell Cure Neurosciences, and Teva Pharmaceuticals on October 10, 2010.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
10/10/2010 | Licensor, and Licensee | Israel | The ongoing development of OpRegenTM by Cell Cure Neurosciences Ltd. is funded through equity investments by BioTime , Inc. , Teva , and Hadasit Bio Holdings , made simultaneously with this agreement . | 1 | |
7/30/2007 | Partner |
Date | 10/10/2010 | 7/30/2007 |
---|---|---|
Type | Licensor, and Licensee | Partner |
Business Partner | ||
Country | Israel | |
News Snippet | The ongoing development of OpRegenTM by Cell Cure Neurosciences Ltd. is funded through equity investments by BioTime , Inc. , Teva , and Hadasit Bio Holdings , made simultaneously with this agreement . | |
Sources | 1 |
Hadasit Bio Holdings Team
3 Team Members
Hadasit Bio Holdings has 3 team members, including current Chief Financial Officer, Yoram Azulai.
Name | Work History | Title | Status |
---|---|---|---|
Yoram Azulai | Chief Financial Officer | Current | |
Name | Yoram Azulai | ||
---|---|---|---|
Work History | |||
Title | Chief Financial Officer | ||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.